CXCR4 and RIF1 Overexpression Induces Resistance of Epithelial Ovarian Cancer to Cisplatin

The chemoresistance of epithelial ovarian cancer (EOC) is a major problem Thus, the search for novel biomarkers associated with cisplatin sensitivity is overwhelming. Previous studies have shown that chemokine receptor (CXCR4) is associated with tumor growth, angiogenesis and distant metastases and replication regulatory timing factor (RIF1) is responsible for repair of double strand DNA breaks. This study, thus, aimed to identify the correlation between CXCR4 and RIF1 overexpression and cisplatin sensitivity in EOC. Patients and methods: Fifty five EOC patients were recruited to assess chemosensitivity of EOC to cisplatin based chemotherapy in Oncology Department, Tanta University Hospitals. Results: The results showed that patients with a higher CXCR4 and RIF1 expression exhibited a significantly lower chemosensitivity, worse overall survival and a poorer progression-free survival. The only prognostic associated with overall survival was CXCR4.